Literature DB >> 14973552

Gene expression profiling of ErbB receptor and ligand-dependent transcription.

Dhara N Amin1, Archibald S Perkins, David F Stern.   

Abstract

Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression profiling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptor-specific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973552     DOI: 10.1038/sj.onc.1207257

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.

Authors:  Daniel L Abravanel; George K Belka; Tien-chi Pan; Dhruv K Pant; Meredith A Collins; Christopher J Sterner; Lewis A Chodosh
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

2.  Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.

Authors:  Shannon E Telesco; Rajanikanth Vadigepalli; Ravi Radhakrishnan
Journal:  Biotechnol J       Date:  2013-12-04       Impact factor: 4.677

3.  The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events.

Authors:  Jennifer L Gilmore; Richard M Gallo; David J Riese
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

4.  Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.

Authors:  Sarah E Pitfield; Ianthe Bryant; Desi J Penington; Gar Park; David J Riese
Journal:  Oncol Res       Date:  2006       Impact factor: 5.574

5.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

6.  Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.

Authors:  Guangyuan Li; Xiaoqi Wang; Hanina Hibshoosh; Cheng Jin; Balazs Halmos
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

7.  Phospholipid Phosphatase 4 promotes proliferation and tumorigenesis, and activates Ca2+-permeable Cationic Channel in lung carcinoma cells.

Authors:  Xin Zhang; Lan Zhang; Bihua Lin; Xingxing Chai; Ronggang Li; Yuehua Liao; Xinghui Deng; Qiongru Liu; Wenli Yang; Yubo Cai; Wei Zhou; Zhichao Lin; Wenhai Huang; Meigong Zhong; Fangyong Lei; Jinhua Wu; Shuaishuai Yu; Xiaoping Li; Shangren Li; Yueyue Li; Jincheng Zeng; Wansheng Long; Dong Ren; Yanming Huang
Journal:  Mol Cancer       Date:  2017-08-29       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.